Literature DB >> 33345719

Long non-coding RNA XIST promotes the progression of esophageal squamous cell carcinoma through sponging miR-129-5p and upregulating CCND1 expression.

Haoran Wang1, Haomiao Li1, Yongkui Yu1, Qingfeng Jiang1, Ruixiang Zhang1, Haibo Sun1, Wenqun Xing1, Yin Li1.   

Abstract

Long non-coding RNA (lncRNA) X inactive specific transcript (XIST) has been identified as an oncogenic lncRNA in a series of human cancers, including esophageal squamous cell carcinoma (ESCC). In this study, we aimed to further explore the underlying mechanism of XIST on ESCC progression. qRT-PCR assay was used to determine the levels of XIST and miR-129-5p. Western blot analysis was performed to assess cyclin D1 (CCND1) expression. Bioinformatic analysis was performed using starBase v2.0 software. Dual-luciferase reporter and RNA immunoprecipitation assays were employed to confirm the interaction between XIST and miR-129-5p or miR-129-5p and CCND1. Cell cycle progression and apoptosis were measured by flow cytometric analysis, and cell migration and invasion were detected by transwell assay. Mouse studies were used to observe the effect of XIST silencing on tumor growth in vivo. Our results indicated that XIST was upregulated and miR-129-5p was downregulated in ESCC. XIST silencing or miR-129-5p overexpression repressed cell cycle progression, proliferation, migration, invasion, and promoted the apoptosis in ESCC cells. Moreover, XIST directly interacted with miR-129-5p and repressed miR-129-5p expression. MiR-129-5p mediated the regulatory effect of XIST on ESCC cell progression in vitro, and XIST promoted CCND1 expression by sponging miR-129-5p. Additionally, XIST silencing inhibited tumor growth in vivo. Our findings suggested that XIST silencing repressed the progression of ESCC at least partly through regulating the miR-129-5p/CCND1 axis. Targeting XIST might be a potential therapeutic strategy for ESCC treatment.

Entities:  

Keywords:  ESCC; X inactive specific transcript (XIST); cyclin D1 (CCND1); miR-129-5p

Mesh:

Substances:

Year:  2020        PMID: 33345719      PMCID: PMC7849746          DOI: 10.1080/15384101.2020.1856497

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  34 in total

1.  MiR-129-5p inhibits non-small cell lung cancer cell stemness and chemoresistance through targeting DLK1.

Authors:  Zheng Ma; Hongfei Cai; Yan Zhang; Liang Chang; Youbin Cui
Journal:  Biochem Biophys Res Commun       Date:  2017-06-12       Impact factor: 3.575

2.  MiR-99a suppresses proliferation, migration and invasion of esophageal squamous cell carcinoma cells through inhibiting the IGF1R signaling pathway.

Authors:  Li-Li Mei; Yun-Tan Qiu; Meng-Bing Huang; Wen-Jun Wang; Jie Bai; Zhi-Zhou Shi
Journal:  Cancer Biomark       Date:  2017-12-06       Impact factor: 4.388

3.  Upregulation of the long non-coding RNA BANCR correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma.

Authors:  Zihao Liu; Tongxin Yang; Zhipeng Xu; Xiufeng Cao
Journal:  Biomed Pharmacother       Date:  2016-05-31       Impact factor: 6.529

4.  Transcriptional and posttranscriptional regulation of HOXA13 by lncRNA HOTTIP facilitates tumorigenesis and metastasis in esophageal squamous carcinoma cells.

Authors:  C Lin; Y Wang; Y Wang; S Zhang; L Yu; C Guo; H Xu
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

5.  LncRNA HULC promotes the progression of gastric cancer by regulating miR-9-5p/MYH9 axis.

Authors:  Tao Liu; Yang Liu; Chongqing Wei; Zhen Yang; Weilong Chang; Xiefu Zhang
Journal:  Biomed Pharmacother       Date:  2019-11-11       Impact factor: 6.529

6.  Long noncoding RNA LOXL1-AS1 regulates prostate cancer cell proliferation and cell cycle progression through miR-541-3p and CCND1.

Authors:  Bo Long; Na Li; Xi-Xia Xu; Xiao-Xin Li; Xin-Jie Xu; Jie-Ying Liu; Zhi-Hong Wu
Journal:  Biochem Biophys Res Commun       Date:  2018-09-29       Impact factor: 3.575

7.  miR-1 suppresses the growth of esophageal squamous cell carcinoma in vivo and in vitro through the downregulation of MET, cyclin D1 and CDK4 expression.

Authors:  Sen Jiang; Chao Zhao; Xiaodi Yang; Xiangyang Li; Qing Pan; Haijin Huang; Xuyang Wen; Husheng Shan; Qianwen Li; Yunxiang Du; Yaping Zhao
Journal:  Int J Mol Med       Date:  2016-05-31       Impact factor: 4.101

8.  LncRNA NEAT1 Regulates Cell Viability and Invasion in Esophageal Squamous Cell Carcinoma through the miR-129/CTBP2 Axis.

Authors:  Yong Li; Dong Chen; Xiang Gao; Xiaohui Li; Gongning Shi
Journal:  Dis Markers       Date:  2017-09-25       Impact factor: 3.434

9.  Down-regulation of miR-129-5p inhibits growth and induces apoptosis in laryngeal squamous cell carcinoma by targeting APC.

Authors:  MingHua Li; LinLi Tian; Lin Wang; HongChao Yao; JiaRui Zhang; JianGuang Lu; YaNan Sun; Xu Gao; Hui Xiao; Ming Liu
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

10.  Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression.

Authors:  Dong-Liang Chen; Huai-Qiang Ju; Yun-Xin Lu; Le-Zong Chen; Zhao-Lei Zeng; Dong-Sheng Zhang; Hui-Yan Luo; Feng Wang; Miao-Zhen Qiu; De-Shen Wang; Da-Zhi Xu; Zhi-Wei Zhou; Helene Pelicano; Peng Huang; Dan Xie; Feng-Hua Wang; Yu-Hong Li; Rui-Hua Xu
Journal:  J Exp Clin Cancer Res       Date:  2016-09-13
View more
  3 in total

1.  lncRNA XIST knockdown suppresses cell proliferation and promotes apoptosis in diabetic cataracts through the miR‑34a/SMAD2 axis.

Authors:  Chao Wang; Ruiling Zhao; Suhong Zhang
Journal:  Mol Med Rep       Date:  2021-11-09       Impact factor: 2.952

Review 2.  Long non-coding RNA XIST: a novel oncogene in multiple cancers.

Authors:  Jun Yang; Manlong Qi; Xiang Fei; Xia Wang; Kefeng Wang
Journal:  Mol Med       Date:  2021-12-20       Impact factor: 6.354

3.  BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma.

Authors:  Kathleen Gebhardt; Bayram Edemir; Elisabeth Groß; Linda Nemetschke; Stefanie Kewitz-Hempel; Rose K C Moritz; Cord Sunderkötter; Dennis Gerloff
Journal:  Cancers (Basel)       Date:  2021-05-15       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.